Type 2 & other diabetes

Sustained Use of SGLT2 Inhibitors and Cardiovascular Outcomes in Older Adults: A Landmark Cohort Study

Diabetes Obes MetabPublished Landmark cohort study

Authors' conclusion

Among older adults who had maintained treatment for ≥ 6 months, sustained SGLT2i use was associated with lower subsequent risks of heart failure hospitalisation and MACE. Heart failure associations were directionally consistent across BMI strata, whereas BMI-related MACE heterogeneity was exploratory

Study context

Population
Adults aged ≥ 65 years with T2D who maintained SGLT2i or DPP-4i for ≥ 6 months, Japan
Participants
24,380 adults
Exposure
Sustained SGLT2i vs DPP-4i
  • SGLT2in = 4,223
  • DPP-4in = 20,157reference
Outcome
HF hospitalisation; MACE:
  • MI
  • Stroke
  • All-cause mortality
Methodological detailsnationwide-scale, linked claims and health examination data, inverse probability of treatment and censoring weighting, weighted discrete-time hazard models
  • Nationwide-scale
  • Linked claims and health examination data
  • Inverse probability of treatment and censoring weighting
  • Weighted discrete-time hazard models

Main finding

As reported in the abstract

Each group vs DPP-4iEstimate (95% CI)
SGLT2i
HR (HF hospitalisation) 0.775(0.628–0.958)
SGLT2i
HR (MACE) 0.848(0.753–0.955)

Observational data: associations, not effects.

Further findings

Stroke

Stroke hazard was lower, HR
0.834 (0.721-0.965) (95% CI)

MI and all-cause mortality

MI and all-cause mortality were not clearly different

HF hospitalisation across body mass index (BMI) strata

Association directionally consistent across BMI strata; p for interaction
0.953

MACE across BMI strata

MACE estimates differed across BMI strata; p for interaction
0.007
  • Exploratory

MACE, lowest BMI group (< 22 kg/m²)

No clear association in lowest BMI group, HR
1.226 (0.931-1.615) (95% CI)
  • Exploratory

Original publication

Sustained Use of SGLT2 Inhibitors and Cardiovascular Outcomes in Older Adults: A Landmark Cohort Study. Diabetes Obes Metab. Published 28 July 2026. doi:10.1111/dom.71151

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.